CurrentBlue Cross Blue Shield - MassachusettsPolicy 308

Biofeedback for Fecal Incontinence and Constipation

This policy governs coverage and prior authorization requirements for biofeedback therapy used to treat constipation (including dyssynergia-type) and fecal incontinence in commercial members of Blue Cross Blue Shield of Massachusetts.

Policy Summary

PayerBlue Cross Blue Shield - Massachusetts

PolicyBiofeedback for Fecal Incontinence and Constipation

Policy CodePolicy 308

Change TypeAnnual literature review — no policy statement changes

Effective Date

Next Review Date

Key ActionObtain prior authorization for inpatient biofeedback services and document Rome IV criteria, a 3‑month trial of standard treatments, and objective physiologic evidence of pelvic floor dyssynergia.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

up to 6 sessionsrecommended treatment course for dyssynergia-type constipation

Rome IVdiagnostic criteria referenced

dyssynergia-typecovered indication

non-dyssynergiainsufficient evidence

fecal incontinence

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Criteria and Indications

Medically necessary — dyssynergia-type constipation

Biofeedback for constipation in adults is MEDICALLY NECESSARY when ALL of the following are met:

Overall requirement: Patient meets Rome IV criteria for functional constipation (e.g., two or more features such as straining, sensation of incomplete evacuation, lumpy/hard stools, sensation of anorectal obstruction, fewer than three defecations per week, or manual maneuvers) with symptoms for the last 3 months and onset at least 6 months prior; the patient has failed a 3-month trial of standard treatments for constipation including laxatives, dietary changes, and exercises; and there is objective physiologic evidence of pelvic floor dyssynergia demonstrated by inappropriate pelvic floor contraction or <20% relaxation of basal resting sphincter pressure by anorectal manometry, imaging, or EMG.<20% relaxation of basal resting sphincter pressure

Recommended treatment course: up to 6 biofeedback sessions over 3 months.

Investigational indications

Biofeedback is considered INVESTIGATIONAL in the following situations:

Investigational uses: Biofeedback as a treatment of constipation in adults and children except for dyssynergia-type constipation; and biofeedback as a treatment of fecal incontinence in adults and children.

Evidence is insufficient to determine net health benefit for these indications.

Evidence-based coverage by indication

Coverage conclusions based on evidence reviews

Dyssynergia-type constipation: Biofeedback is supported by several well-conducted randomized controlled trials and two systematic reviews showing benefits in patients meeting well-defined dyssynergia criteria; evidence sufficient to determine improvement in net health outcome.

Covered for dyssynergia-type constipation.

Fecal incontinence: Most trials have not shown a consistent benefit; systematic reviews have not found that biofeedback plus conventional therapy provides additional benefit compared with conventional therapy alone; evidence insufficient to determine improvement in net health outcome.

Not established as effective overall.

Constipation other than dyssynergia: Systematic reviews and RCTs include heterogeneous populations combining dyssynergia and non-dyssynergia types; biofeedback has not been clearly beneficial for nondyssynergia constipation and evidence is insufficient to determine improvement in net health outcome.

Not covered as an established therapy for non-dyssynergia constipation.

Biofeedback is considered investigational for treatment of constipation when the presentation is not dyssynergia-type. The policy specifies that biofeedback is medically necessary only for patients meeting the defined criteria for dyssynergia-type constipation; in all other constipation situations in adults and children, biofeedback is investigational. Evidence for non-dyssynergia constipation includes randomized trials and systematic reviews with heterogeneous populations and outcomes, and these data do not clearly demonstrate net health benefit for non-dyssynergia presentations.

No explicit procedural exclusions are listed in this policy fragment beyond the indication-based exclusions described elsewhere. The document frames exclusions by clinical indication (e.g., constipation other than dyssynergia-type and fecal incontinence are considered investigational) rather than by specific procedural settings or techniques.

For fecal incontinence, the available evidence (RCTs and systematic reviews) is mixed: one RCT showed improvement with biofeedback plus exercise compared with exercise alone, but most trials and systematic reviews have not demonstrated consistent additional benefit of biofeedback plus conventional therapy. Consequently, the evidence is insufficient to determine that biofeedback improves net health outcomes for fecal incontinence in adults or children.

In summary, evidence supports biofeedback as medically necessary only for dyssynergia-type constipation, where multiple well-conducted RCTs and two systematic reviews have shown benefit. For other constipation types and for fecal incontinence, systematic reviews and trials are heterogeneous and generally do not demonstrate consistent benefit; therefore these indications are characterized as having insufficient evidence to establish improvement in net health outcome and are considered investigational in this policy.

Procedure and Diagnosis Codes

CPT Codes for biofeedbackCPT

90875	Individual psychophysiological therapy incorporating biofeedback training by any modality (face-to-face with the patient), with psychotherapy; approximately 20-30 minutes.
90876	Individual psychophysiological therapy incorporating biofeedback training by any.
90901	Biofeedback training by any modality.
90912	Biofeedback training; perineal muscles, anorectal or urethral sphincter, including EMG and/or manometry, when performed; initial 15 minutes of one-on-one physician.
90913	Biofeedback training; perineal muscles, anorectal or urethral sphincter, including EMG and/or manometry, when performed; each additional 15 minutes of one-on-one physician or other qualified health care professional contact with the patient (List separately, in addition to code for primary procedure).

ICD-10 Diagnosis CodesICD-10

K59.02	Outlet dysfunction constipation.
R15.0	Incomplete defecation.

ICD-10 Procedure CodesICD-10

GZCIZZZ

Biofeedback (ICD-10-PCS).

Coding notesmixed

No codes listed

Pelvic floor relaxation threshold — clinical definition/measurement

Threshold< 20% relaxation of basal resting sphincter pressure

Measurement methodsDemonstrated by manometry, imaging, or EMG using age- and sex-appropriate normal values

Context for abnormal resultOccurs during attempted defecation with adequate propulsive forces

Prior Authorization, Documentation, and Operational Notes

Prior Authorization

Prior Authorization Required

Precertification/preauthorization is required for inpatient services described in this policy. Outpatient prior authorization requirements vary by product; commercial PPO and Indemnity outpatient services do not require prior authorization. Providers should verify benefit-specific requirements and obtain authorization when required before scheduling services.

Inpatient: Prior authorization required for all products when procedure is performed inpatient.
Outpatient: Prior authorization may be required depending on product; Commercial PPO and Indemnity outpatient = Prior authorization not required.
Verify member benefits and obtain precertification where applicable prior to service.

Documentation Required

Required Clinical Documentation for Medical Necessity

Document clinical evidence that the member meets medical necessity criteria before requesting authorization. Include objective physiologic testing results and a record of prior conservative therapy trials.

Clinical Background

Constipation is categorized into subtypes including normal-transit, slow-transit, and dyssynergic defecation (loss of coordinated pelvic floor relaxation during defecation). The policy emphasizes that biofeedback targets pelvic floor dysfunction: trials focusing on the dyssynergia-type subgroup—defined by Rome IV criteria plus objective physiologic evidence of inappropriate pelvic floor contraction or <20% relaxation of basal resting sphincter pressure—have demonstrated benefit, whereas evidence for other constipation subtypes is inconclusive.

Key Definitions

Dyssynergic defecation — definition and diagnostic threshold

DefinitionInappropriate contraction of the pelvic floor or less than 20% relaxation of basal resting sphincter pressure during attempted defecation

Required accompanying conditionMust occur with adequate propulsive forces during attempted defecation

Reference standardsCriteria defined by age- and sex-appropriate normal values for the technique

Fecal incontinence — definition and contributing factors

DefinitionRecurrent uncontrolled passage of fecal material

Contributing factorsMultifactorial pathophysiology including intestinal motility (diarrhea or constipation), poor rectal compliance, impaired rectal sensation, or weak/damaged pelvic floor muscles